Fox Run Management L.L.C. Purchases New Holdings in Haemonetics Corporation $HAE

Key Points

• Fox Run Management L.L.C. has acquired a new stake in Haemonetics Corporation, purchasing 11,191 shares valued at approximately $711,000.
• Several hedge funds, including Voya Investment Management and The Manufacturers Life Insurance Company, significantly increased their holdings in Haemonetics in the last quarter, showcasing strong institutional interest.
• Haemonetics recently reported earnings per share (EPS) of $1.10, beating analysts' expectations, though the company's quarterly revenue saw a year-over-year decline of 4.4%.

Fox Run Management L.L.C. acquired a new position in Haemonetics Corporation (NYSE:HAE - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 11,191 shares of the medical instruments supplier's stock, valued at approximately $711,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. TD Waterhouse Canada Inc. purchased a new stake in shares of Haemonetics during the fourth quarter worth about $25,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Haemonetics during the 1st quarter valued at about $65,000. KBC Group NV boosted its holdings in Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after purchasing an additional 401 shares during the last quarter. Vise Technologies Inc. grew its stake in shares of Haemonetics by 8.7% in the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after buying an additional 225 shares during the period. Finally, CWC Advisors LLC. increased its holdings in shares of Haemonetics by 7.4% during the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock worth $241,000 after buying an additional 212 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on HAE. Raymond James Financial cut Haemonetics from a "strong-buy" rating to an "outperform" rating and cut their target price for the stock from $105.00 to $78.00 in a research note on Monday, August 11th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $62.00 price objective (down from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Robert W. Baird initiated coverage on Haemonetics in a research report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 target price on the stock. Barrington Research decreased their price target on Haemonetics from $95.00 to $86.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $85.18.

Haemonetics Stock Up 3.6%

Haemonetics stock traded up $1.9560 during mid-day trading on Friday, hitting $55.9360. The company had a trading volume of 320,976 shares, compared to its average volume of 809,128. Haemonetics Corporation has a 1 year low of $50.68 and a 1 year high of $94.99. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of 17.14, a PEG ratio of 1.00 and a beta of 0.40. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. The business has a fifty day moving average of $69.78 and a 200 day moving average of $66.41.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.09. The business had revenue of $321.39 million for the quarter, compared to analysts' expectations of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business's revenue was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, sell-side analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.